- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.04. | Estrella Immunopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.03. | Estrella Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.02. | Estrella Immunopharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 30.01. | Estrella Immunopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.12.23 | Estrella Immunopharma, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 20.11.23 | Estrella Immunopharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.11.23 | Estrella Immunopharma, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | - | SEC Filings | ||
| 13.11.23 | Estrella Immunopharma, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 29.09.23 | TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination | 149 | PR Newswire | Estrella to Begin Trading on NASDAQ Under the Ticker Symbols "ESLA" and "ESLAW" Beginning October 2, 2023
NEW YORK, Sept. 29, 2023 /PRNewswire/ -- Estrella Immunopharma, Inc., formerly known as... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DAY ONE BIOPHARMACEUTICALS | 16,600 | -3,32 % | Day One Biopharmaceuticals GAAP EPS of -$0.72 misses by $0.06 | ||
| CG ONCOLOGY | 35,100 | 0,00 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,940 | 0,00 % | Recursion (RXRX) to Report Q1 Earnings: What's in the Cards? | ||
| JANUX THERAPEUTICS | 62,19 | -4,00 % | Aktien New York: Dow erholt sich vor Start in die Berichtssaison | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben sich am Donnerstag im Handelsverlauf von ihrer anfänglichen Schwächephase erholt. Der Dow Jones Industrial notierte zuletzt 0,12 Prozent im Plus bei 38... ► Artikel lesen | |
| IMMUNOVANT | 29,670 | +2,88 % | Pre-market Movers: Kaival Brands, Lufax Holding, Tourmaline Bio, Laser Photonics Corporation, Immunovant | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.00 A.M. ET).In the Green Kaival Brands Innovations Group... ► Artikel lesen | |
| KEROS THERAPEUTICS | 60,26 | 0,00 % | Keros Therapeutics files automatic mixed shelf | ||
| BEAM THERAPEUTICS | 22,780 | -1,51 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 39,740 | +1,15 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights | Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024 Phase 2b study in obesity... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 10,390 | +2,36 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| ARVINAS | 32,260 | -1,77 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
| ARCELLX | 52,67 | 0,00 % | Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights | -- Expanded strategic partnership with Kite --
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 20,600 | -3,69 % | Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| NUVALENT | 69,25 | 0,00 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 19,990 | 0,00 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth -- ARCALYST 2024 expected net product revenue increased to $370 - $390 million -- Abiprubart... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 10,000 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory... ► Artikel lesen |
ESTRELLA IMMUNOPHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,040 (+4,00 %) liegt der Kurs bei 1,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
